22 January 2021 : Original article
Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
Hyung Duk Kim1BEF, Ji-Yeun Chang1CDE, Byung Ha Chung1AB, Chan-Duck Kim2B, Sang-Ho Lee3B, Yeong Hoon Kim4B, Chul Woo Yang1ADG*DOI: 10.12659/AOT.927984
Ann Transplant 2021; 26:e927984
Table 1 Comparison of baseline characteristics (ITT population).
| EVL group (n=38) | TAC group (n=39) | P-value | |
|---|---|---|---|
| 44.71±11.63 | 46.49±11.78 | 0.507 | |
| 19 (50.00) | 20 (51.28) | 0.914 | |
| 3 (7.89) | 2 (5.13) | 0.6748 | |
| 0.2397 | |||
| Hypertension | 7 (18.42) | 10 (25.64) | |
| Nephrosclerosis | 1 (2.63) | 1 (2.56) | |
| IgA nephropathy | 11 (28.95) | 7 (17.95) | |
| Other glomerulonephritis | 11 (28.95) | 4 (10.26) | |
| Polycystic kidney disease | 2 (5.26) | 3 (7.69) | |
| Unknown | 5 (13.16) | 11 (28.21) | |
| Other | 1 (2.63) | 2 (5.13) | |
| A (0, 1, 2) | 9 (23.68), 22 (57.89), 7 (18.42) | 6 (15.38), 22 (56.41),10 (25.64)* | 0.5712 |
| B (0, 1, 2) | 7 (18.42), 16 (42.11), 15 (39.47) | 4 (10.26), 14 (35.90), 20 (51.28)* | 0.4339 |
| DR (0, 1, 2) | 5 (13.16), 20 (52.63), 13 (34.21) | 7 (17.95), 18 (46.15), 13 (33.33)* | 0.8627 |
| 0.3155 | |||
| Hemodialysis, n (%) | 23 (60.53) | 27 (69.23) | |
| Peritoneal dialysis, n (%) | 10 (26.32) | 5 (12.82) | |
| 5.30±12.05 | 4.44±12.26 | 0.6069 | |
| Donor type | 0.8594 | ||
| Living related, n (%) | 15 (39.47) | 15 (38.46) | |
| Living-unrelated, n (%) | 6 (15.79) | 8 (20.51) | |
| * No results in one patient. Discrete variables are presented with n (%), and continuous variables with normal distributions are presented with mean±S.D. HLA – human leukocyte antigen; PRA – panel-reactive antibody. | |||